2026年5月12日—15日，全球肥胖领域重磅盛会之一——第33届欧洲肥胖大会（ECO 2026）将于土耳其伊斯坦布尔隆重举办！ECO大会自创办以来，始终聚焦肥胖研究与临床管理前沿，搭建全球学术交流平台。本次大会汇聚全球顶尖专家，围绕肥胖领域热点、难点问题，开展学术研讨与成果分享。

大会覆盖四大核心板块：基础科学、行为科学与公共卫生、儿童青少年肥胖、肥胖管理与干预，同时设置主旨演讲、专题研讨等多种形式，促进全球同仁交流合作。值得关注的是，多位中国顶尖专家将受邀登台，立足中国实践，向全球分享中国经验、发出中国声音。

让我们共同期待这场学术盛宴，期待中国专家在国际舞台上的精彩表现，也期待全球肥胖领域同仁携手并肩，共探肥胖科学发展新方向，共筑全民健康新未来！

欢迎加入

ECO 2026学术交流群

如有您特别关注的讲题，欢迎加入交流群联系学术小助手，我们将及时与您共享会议现场采集的相关资料。

中国专家·专题汇报

5月13日

PO1.004：Late but not early exercise alleviates MASLD by promoting gut microbial conversion of lactate into short-chain fatty acids

延迟但非过早的运动可通过促进肠道微生物将乳酸转化为短链脂肪酸来缓解MASLD

当地时间：18:10-18:15

北京时间：23:10-23:15讲者：Sen Zhang

PO1.009：Aerobic Exercise Attenuates Brown Adipose Tissue Whitening by Modulating the Galectin-1 Axis in High-Fat Diet-Induced Obese Mice

有氧运动通过调节半乳糖凝集素-1轴减轻高脂饮食诱导肥胖小鼠的棕色脂肪组织白化

当地时间：18:35-18:40

北京时间：23:35-23:40讲者：Chi Chang Huang

5月14日

AD11.03：Discovery of a Novel Bioactive Small Molecule with Dual Anti-Obesity and Anti-Diabetic Activity

一种兼具双重抗肥胖与抗糖尿病活性的新型生物活性小分子的发现

当地时间：11:50-12:00

北京时间：16:50-17:00讲者：Dongmin Liu

AD11.08：Pharmacological Nicotinamide N-methyltransferase inhibition improves dyslipidemia and attenuates atherosclerosis development in mice

烟酰胺N-甲基转移酶药理学抑制可改善小鼠血脂异常并减轻动脉粥样硬化进展

当地时间：12:40-12:50

北京时间：17:40-17:50讲者：Kaiming Yue

AD17.03：The effect of excess adiposity on cancer risk through insulin resistance and glucose control among adults without diabetes: a causal mediation analysis (China and UK)

非糖尿病成年人群中过度肥胖通过胰岛素抵抗与血糖调控影响癌症发病风险：一项中英因果中介分析

当地时间：17:15-17:30

北京时间：22:15-22:30讲者：Xintong Lu

AD16.05：Prevalence Trends and Multidimensional Disparities in Among Younger Older Adults living with obesity in China: Analysis of Six National Physical Fitness Surveillance Data (2000–2025)

中国低龄老年人群肥胖流行趋势及多维差异分析：基于2000年~2025年六次国民体质监测数据

当地时间：17:45-18:00

北京时间：22:45-23:00讲者：Chao Qun Fan

PO2.008：Obesity and Public Health Policy in Taiwan: Gaps Between Clinical Evidence, Cultural Norms, and Prevention Strategies

中国台湾地区肥胖与公共卫生政策：临床证据、文化规范与预防策略之间的差距

当地时间：18:35-18:40

北京时间：23:35-23:40讲者：Wan Yi Shen

PO4.001：Effects of early versus late time-restricted eating on body weight and body composition in adults with overweight and metabolic syndrome: a randomized controlled trial

早期限时进食与晚期限时进食对超重及代谢综合征成年人体重与身体成分的影响：一项随机对照试验

当地时间：18:00-18:05

北京时间：23:00-23:05讲者：Mingqian He

LBP4.006：Relationship Between Relative Fat Mass and Stress Urinary Incontinence in Adult Women with Overweight and Obesity: Findings from NHANES 2011–2018

超重与肥胖成年女性相对脂肪量与压力性尿失禁的相关性：基于NHANES 2011~2018数据的研究结果

当地时间：18:25-18:30

北京时间：23:25-23:30讲者：Tingting Zhu

5月15日

AD18.06 Association of Sunlight Exposure With Gut Microbiota and Body Weight in Preschool Children: A Cross-Sectional Study

学龄前儿童日照暴露与肠道菌群及体重的关联性：一项横断面研究

当地时间：10:20-10:30

北京时间：15:20-15:30讲者：Gengsheng He

中国专家·壁报展示

PO1.011：Correlation between erythritol and metabolic dysfunction-associated steatotic liver disease in overweight/obesity

超重/肥胖人群中赤藓糖醇与代谢相关脂肪性肝病的相关性

作者：Jing Ma, Tao Tan, Jiang Yue, Yicheng Qi, Minglan Yang

PO1.020：An ALK7 siRNA developed by GenSci adipose delivery platform showed excellent activity in pre-clinical studies

由GenSci脂肪递送平台开发的ALK7 siRNA在临床前研究中显示出优异活性

作者：Li Xia, Shi Chen, Jing Ma, Yuanfeng Xia, Wenqiang Zhai, Fanglong Yang, Siqin Wang, Lei Jin

PO1.092：Long-term serum 25-hydroxyvitamin D levels and body composition, including visceral fat area and body fat percentage: The prospective HUNT Study

长期血清25-羟基维生素D水平与身体成分（包括内脏脂肪面积和体脂百分比）：前瞻性HUNT研究

作者：Xiaomei Mai, Thea Wøyen Hamfjord, Yiqian Sun

PO1.106：Association between BMI and efffcacy of neoadjuvant chemo-immunotherapy in operable triple-negative breast cancer patients

可手术三阴性乳腺癌患者BMI与新辅助化疗联合免疫治疗疗效的相关性

作者：Yubo Shi, Yuxin Deng, Zhijun Liu, Jieqiong Liu

PO1.124：Losses of Fat-Free Mass, Skeletal Muscle Mass, and Organ Mass After Weight Loss: A Systematic Review and Meta-analysis

体重减轻后去脂体重、骨骼肌质量及器官质量的损失：系统评价与荟萃分析

作者：Junyi Guo, Niamh Krik, Jia Jiet Lim, Kristine Beaulieu, R James Stubbs, Mark Hopkins

PO2.036：Snack preferences among Chinese school-aged children: evidence from discrete choice experiments

中国学龄儿童零食偏好：基于离散选择实验的证据

作者：Wenwen Du, Chang Su, Huijun Wang

PO2.087：Age-Specific Associations Between Body Mass Index and All-Cause Mortality in Adults: Implications for Obesity Assessment Across the Lifecourse

成年人群体质指数与全因死亡率的年龄特异性关联：对全生命周期肥胖评估的启示

作者：Wan Yi Shen

PO2.112：Analysis of Milk Consumption and Associated Factors among Primary and Secondary School Students in Beijing

北京市中小学生牛奶消费情况及相关因素分析

作者：Liyu Huang

PO2.114：Body Fat Percentage Modulates the Sex-Specific Dose-Response Relationship Between Cardiorespiratory Fitness and Cognitive Function in Older Adults: A cross-sectional analysis of 48,770 participants from China

体脂百分比调节老年人心肺适能与认知功能之间的性别特异性剂量-反应关系：基于中国48 770名参与者的横断面分析

作者：Chao Qun Fan, Kai Kai Xu, Zong Hao Sun

PO2.121：The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictor of cardiovascular and all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES Ⅲ

非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值作为代谢功能障碍相关脂肪性肝病患者心血管死亡率及全因死亡率的预测指标：来自 NHANES Ⅲ的证据

作者：Zongliang Yu, Lingling Li, Rui Gao

PO2.122：Longitudinal associations between lifestyle patterns and health-related quality of life in adults with type 2 diabetes and obesity

2型糖尿病合并肥胖成年人群生活方式与健康相关生活质量的纵向关联

作者：Qian Zou, Rafael Ogaz González, Gerton Lunter, Eva Corpeleijn

PO2.128：Identifying Optimal Obesity-Related Indicators for Hypertension Prediction and Their Dose-Response Relationships in a National Survey of 110,000 Chinese Adults

基于中国11万成年人群全国调查的高血压预测最优肥胖相关指标筛选及其剂量-反应关系

作者：Jingjing Wang, Chenglong Wang

PO2.129：Clinical Obesity among Chinese Adults: Prevalence, Multi-morbidity Burden, and Associations with Physical Activity

中国成年人群临床肥胖患病率、共病负担及其与体力活动的关联

作者：Zhuoren Wang, Changchang Su, Wenwen Du, Huijun Wang

PO2.148：Beyond Clinical Care: China’s Population-Level Strategies in Obesity Prevention and Control

超越临床诊疗：中国肥胖防控的人群级策略

作者：Yueyi Tong

PO4.068：From face-to-face to telehealth and digital intervention: a journey of developing a suite of obesity prevention programs in early childhood in Australia

从面对面干预到远程医疗与数字化干预：澳大利亚幼儿肥胖防控系列项目的开发历程

作者：Li Ming Wen, Huilan Xu, Sarah Taki, Philayrath Phongsavan, Alison Hayes, Louise Baur

PO4.181：Effects of early, late and self-selected time-restricted eating on pancreatic fat in men and women with overweight or obesity: a secondary analysis of a multicenter randomized controlled trial

早期限时、晚期限时与自主选择限时进食对超重/肥胖男女性胰腺脂肪的影响：一项多中心随机对照试验的二次分析

作者：Dongping Guo, Marcos Molina Fernandez, Antonio Clavero Jimeno, Manuel Dote Montero, Maddi Osés, María Medrano

PO4.263：ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, demonstrated 14-day average observed half-life, 6-fold longer than tirzepatide, in NHP model and 71% more relative weight loss than tirzepatide in DIO mouse model

新一代每月一次GLP-1R/GIPR双受体激动剂多肽ASC35在非人灵长类模型中观察半衰期达14天，为替尔泊肽的6倍；在饮食诱导肥胖小鼠模型中相对减重效果较替尔泊肽高71%

作者：Jinzi Jason Wu, Kunhua Dong, Chengfei Wu

PO4.264：ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy

ASC47联合司美格鲁肽在肥胖患者中显示出比司美格鲁肽单药治疗高达111.8%的相对体重减轻幅度

作者：Jinzi Jason Wu, Yike Li

PO4.270：ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in NHP model and 91% more relative weight loss than petrelintide in DIO rat model

新一代每月一次胰淀素受体激动剂多肽ASC36在非人灵长类模型中观察半衰期达32天，为petrelintide的6倍；在饮食诱导肥胖大鼠模型中相对减重效果较petrelintide高91%

作者：Jinzi Jason Wu, Kunhua Dong, Chengfei Wu

PO4.282：SYH2092, a Long-Acting Biased Amylin Agonist discovered through AI-driven platform, showed superior weight loss efficacy and sustained exposure in preclinical studies

基于AI平台发现的长效偏向性胰淀素激动剂SYH2092在临床前研究中展现更优减重疗效与持续暴露水平

作者：Jingyi Gao, Ying Yan, Min Wang, Zhen Xu, Quan Wang, Zhengsheng Liu, Linlin Xiao, Yang Zhang, Xiaojun Zhang, Lili Cui, Yajuan Wang, Mo Dan

PO4.332：An Observational Study on Rates of Gastric Emptying in Patients with Obesity

肥胖患者胃排空速率的观察性研究

作者：Jing Ma

PO4.515：The association between muscle-to-fat ratio and risk of prediabetes in high-risk adults

高危成年人群肌脂比与糖尿病前期风险的关联

作者：Haiyan Yang, Xiaohui Feng, Tingting Lv, Yan Tang, Sheng Ge, Shuyao Hua

LBP1.021：Defining an AGEs–Adipose–Kidney Axis: Extracellular Vesicles Drive Renal Fibrosis Through Interorgan Crosstalk

定义晚期糖基化终产物–脂肪–肾脏轴：细胞外囊泡通过器官间串扰介导肾纤维化

作者：Yibin Ma, Shan Lin, Xiaoxing Mo, Linyan Li, Kailiang Chen, Liegang Liu

LBP2.026：Does living with obesity during tertiary education affect employment outcomes after graduation? Longitudinal evidence on 1,673 young adults in China

作者：Xiaoxiang Dai, Andrew Hill, Daniel Howdon, Miaoqing Yang, Adam Martin

LBP2.039：Regional heterogeneity of dietary patterns and associations with impaired fasting glucose among adults in seven geographic regions of China

中国七大地理区域成年人群膳食模式的区域异质性及其与空腹血糖受损的关联

作者：Aidong Liu, Chang Su, Huijun Wang, Wenwen Du

LBP2.062：Development of a new measure examining the sources and types of experienced weight stigma: a Delphi study

体重歧视经历来源与类型评估新量表的开发：一项德尔菲研究

作者：Yue Wang, Jason Cg Halford, Alice R. Kininmonth, Stuart Flint, Alison Fildes

LBP4.027：Sex-specific mediators of serum uric acid reduction following metabolic bariatric surgery: a longitudinal study

代谢减重手术术后血尿酸降低的性别特异性中介因素：一项纵向研究

作者：Chuyan Tong, Mutailipu Kelibinuer, Ruoyu Chen, Le Bu, Shen Qu, Xin Wen, Yunqing Li, Xiaojuan Zha

LBP4.066：Efficacy and Safety of Semaglutide During Dose-Escalation: STEP 1, 3, 4, 5, 6 and 7

司美格鲁肽剂量递增阶段的疗效与安全性：STEP 1/3/4/5/6/7 研究汇总

作者：Yiming Mu, Yan Yang, Xiaolei Bao, Dongmei Liu

LBP4.073：TQ-lm-10: a potent fully human ActRIIA/B antibody enhancing weight loss quality by preventing muscle loss and accelerating fat reduction

TQ-lm-10：强效全人源ActRIIA/B抗体，通过预防肌肉流失、加速脂肪分解提升减重质量

作者：Na Rong, Zheng Ping Zhang, Kai Di Zhao, Jun Guo, Han Zhou

LBP4.123：Comparative Diabetes Outcomes of Endoscopic Sleeve Gastroplasty and Alternative Weight-Loss Strategies in Asian Populations

亚洲人群内镜袖状胃成形术与其他减重方案的糖尿病结局比较

作者：Yi-Hua Wu, Chih-Kun Huang, Wen-Yuan Lin, Cheng Chieh Lin